Literature DB >> 27107722

Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.

J Alejandro Rauh-Hain1, Rafael Gonzalez1, Amy J Bregar1, Joel Clemmer1, Abraham Hernández-Blanquisett1, Rachel M Clark1, John O Schorge1, Marcela G Del Carmen2.   

Abstract

OBJECTIVE: The aim of this study is to determine if outcomes of patients with ovarian carcinosarcoma (OCS) differ from those of women with high-grade papillary serous ovarian carcinoma (HG-PSOC) when compared by stage and treatment modalities.
METHODS: The National Cancer Database was queried to identify patients with OCS and HG-PSOC diagnosed between 2003 and 2011. Demographic and clinical data were compared, and the impact of tumor histology on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model.
RESULTS: The final study group consisted of 45,153 women. 2886 (6.39%) had OCS and 42,267 (93.61%) had HG-PSOC. The mean age at diagnosis was 65.43 (±12.21) years for women with OCS and 61.52 (±12.6) years for HG-PSOC (P<0.001). African-American women had higher rate of OCS relative to white non-hispanic women (7.84% vs. 6.37%; P=0.002). Overall, women with OCS had a worse five-year survival rate, 26.63% [95% Confidence Interval (CI)=24.86%-28.53%] vs. 43.61% (95% CI=43.07%-44.17%). This difference persisted for each FIGO disease stage I-IV, with five-year survival consistently worse for women with OCS compared to those with HG-PSOC. Over the entire study period and after adjusting for histology, age, period of diagnosis, SEER registry, marital status, stage, surgery, radiotherapy, and lymph node dissection, carcinosarcoma histology was associated with decreased survival.
CONCLUSION: OCS is associated with a poor prognosis compared to HG-PSOC. This difference was noted across all FIGO stages.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinosarcoma; Chemotherapy; Ovarian cancer

Mesh:

Year:  2016        PMID: 27107722     DOI: 10.1016/j.ygyno.2016.04.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.

Authors:  Ibrahim Yalcin; Mehmet Mutlu Meydanli; Ahmet Taner Turan; Salih Taskin; Mustafa Erkan Sari; Tayfun Gungor; Ozgur Akbayir; Ali Ayhan
Journal:  Int J Clin Oncol       Date:  2017-11-16       Impact factor: 3.402

2.  Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.

Authors:  Jun Zhu; Hao Wen; Xingzhu Ju; Rui Bi; Wenjia Zuo; Xiaohua Wu
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

3.  A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel.

Authors:  Nicholas King; Keshav Kukreja; Albina Murzabdillaeva; Yasir Ali; Jason Willis; Abhishek Maiti; Hilary Ma; Joan Bull
Journal:  Clin Sarcoma Res       Date:  2019-07-02

4.  Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience.

Authors:  Aaron Nizam; Bethany Bustamante; Weiwei Shan; Karin K Shih; Jill S Whyte; Antoinette Sakaris; Lisa Dos Santos; Marina Frimer; Andrew W Menzin; Alexander Truskinovsky; Gary L Goldberg
Journal:  Diagnostics (Basel)       Date:  2019-11-22

5.  Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.

Authors:  Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

6.  Management of a rare ovarian carcinosarcoma: A case report and literature review.

Authors:  Jun Fu
Journal:  Exp Ther Med       Date:  2022-07-19       Impact factor: 2.751

7.  Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma.

Authors:  Wen-Peng Wang; Ning Li; Yuan-Yuan Zhang; Yu-Tao Gao; Yang-Chun Sun; Li Ge; Ling-Ying Wu
Journal:  Cancer Manag Res       Date:  2018-07-10       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.